{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:14:00Z","timestamp":1754194440379,"version":"3.41.2"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2019.00017","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T04:52:37Z","timestamp":1552366357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach"],"prefix":"10.3389","volume":"6","author":[{"given":"Daniele","family":"Pastori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rony","family":"Gingis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.11909\/j.issn.1671-5411.2017.03.011","article-title":"Atrial fibrillation: the current epidemic","volume":"14","author":"Morillo","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","article-title":"A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study","volume":"113","author":"Stewart","year":"2002","journal-title":"Am J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1161\/STROKEAHA.116.013378","article-title":"Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registry","volume":"47","author":"Perera","year":"2016","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.14-2414","article-title":"Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors","volume":"147","author":"Pastori","year":"2015","journal-title":"Chest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e003347","DOI":"10.1161\/JAHA.116.003347","article-title":"Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms","volume":"5","author":"Violi","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","article-title":"Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF","volume":"4","author":"Pokorney","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/FJC.0000000000000129","article-title":"Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation","volume":"64","author":"Jia","year":"2014","journal-title":"J Cardiovasc Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"J Am Med Assoc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e000250","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/eurheartj\/ehv476","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665.","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society","author":"January","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2015.08.033","article-title":"Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database","volume":"66","author":"van den Ham","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.116.022802","article-title":"Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation","volume":"134","author":"Oldgren","year":"2016","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"EP Europace"},{"key":"B25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10840-014-9930-y","article-title":"Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"40","author":"Caldeira","year":"2014","journal-title":"J Int Cardiac Electrophysiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ahj.2013.12.014","article-title":"Reasons for warfarin discontinuation in the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF)","volume":"168","author":"O'Brien","year":"2014","journal-title":"Am Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2018","journal-title":"Europace"},{"key":"B29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11739-015-1326-1","article-title":"Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score","volume":"11","author":"Pastori","year":"2016","journal-title":"Int Emerg Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2017.09.154","article-title":"Adverse cardiovascular outcomes in atrial fibrillation: validation of the new 2MACE risk score","volume":"249","author":"Polovina","year":"2017","journal-title":"Int J Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.amjcard.2017.09.003","article-title":"Usefulness of the 2MACE score to predicts adverse cardiovascular events in patients with atrial fibrillation","volume":"120","author":"Rivera-Caravaca","year":"2017","journal-title":"Am J Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/eurheartj\/ehw565","article-title":"A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"38","author":"Fanola","year":"2017","journal-title":"Eur Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ahj.2017.11.004","article-title":"Prediction of long-term net clinical outcomes using the TIMI-AF score: comparison with CHA2DS2-VASc and HAS-BLED","volume":"197","author":"Rivera-Caravaca","year":"2018","journal-title":"Am Heart J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1253\/circj.CJ-17-1318","article-title":"Comparison of the 2MACE and TIMI-AF scores for composite clinical outcomes in anticoagulated atrial fibrillation patients","volume":"82","author":"Pastori","year":"2018","journal-title":"Circulation J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijcard.2015.08.054","article-title":"Inadequate anticoagulation by Vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation","volume":"201","author":"Pastori","year":"2015","journal-title":"Int J Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Int Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ahj.2018.03.004","article-title":"Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation","volume":"200","author":"Pastori","year":"2018","journal-title":"Am Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/07853890.2018.1460489","article-title":"Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice","volume":"50","author":"Li","year":"2018","journal-title":"Ann Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eu Heart J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban once daily, oral, direct factor xa inhibition compared With Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review","volume":"10","author":"Wilke","year":"2017","journal-title":"Patient"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1093\/europace\/eux240","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)","volume":"117","author":"Lip","year":"2017","journal-title":"Europace"},{"key":"B47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.hrthm.2017.11.026","article-title":"Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients treated with vitamin K antagonists: a review","volume":"15","author":"Zulkifly","year":"2017","journal-title":"Heart Rhythm"},{"key":"B48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bj\u00f6rck","year":"2016","journal-title":"JAMA Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejim.2018.04.007","article-title":"Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation","volume":"54","author":"Pastori","year":"2018","journal-title":"Eur J Int Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jacc.2018.06.065","article-title":"Outcomes among patients with atrial fibrillation and appropriate anticoagulation control","volume":"72","author":"Bonde","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e006814","DOI":"10.1161\/JAHA.117.006814","article-title":"Prediction score for anticoagulation control quality among older adults","volume":"6","author":"Lin","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e006669","DOI":"10.1161\/JAHA.117.006669","article-title":"Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation","volume":"6","author":"Williams","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"B53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.amjcard.2017.06.005","article-title":"Anticoagulation control in warfarin-treated patients undergoing cardioversion of atrial fibrillation (from the edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation trial)","volume":"120","author":"Lip","year":"2017","journal-title":"Am J Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"NE J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1756284818793561","DOI":"10.1177\/1756284818793561","article-title":"Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician","volume":"11","author":"Basili","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","article-title":"Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"264","author":"Pastori","year":"2018","journal-title":"Int J Cardiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.dib.2018.01.109","article-title":"Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"17","author":"Pastori","year":"2018","journal-title":"Data Brief"},{"key":"B58","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.amjmed.2018.06.012","article-title":"Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) pathway","volume":"131","author":"Proietti","year":"2018","journal-title":"Am J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.10.022.","article-title":"Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: The ABC (Atrial fibrillation Better Care) pathway in the ATHERO-AF study cohort","author":"Pastori","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.01.003","article-title":"ABC (Atrial fibrillation Better Care) pathway and healthcare costs in atrial fibrillation. The ATHERO-AF study","author":"Pastori","year":"2019","journal-title":"Am J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on control of anticoagulation of the S, standardization committee of the international society on t, haemostasis. definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thrombos Haemost."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC Expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology task force on expert consensus decision pathways","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"New Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"New Engl J Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"Hacke","year":"2008","journal-title":"New Engl J Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association\/american stroke association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"B69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacc.2018.04.036","article-title":"Risk of myocardial infarction in anticoagulated patients with atrial fibrillation","volume":"72","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"New Engl J Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"New Engl J Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2018","journal-title":"Eur Heart J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2019.00017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T04:52:39Z","timestamp":1552366359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2019.00017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":74,"alternative-id":["10.3389\/fcvm.2019.00017"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2019.00017","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"article-number":"17"}}